Insulin glargine doesn't affect cancer rate in diabetes

06/27/2013 | MedPage Today (free registration) · Healio

Insulin glargine did not increase the incidence of cancer in patients with prediabetes and diabetes, researchers reported at the ADA 73rd Scientific Sessions. Data showed the rate of cancer was 1.32 per 100 person-years in the glargine and standard care groups at six years, while the unadjusted rates of cancer-related mortality were 0.54 per 100 person-years in the standard group and 0.51 per 100 person-years in the glargine group.

View Full Article in:

MedPage Today (free registration) · Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI